The state of Maryland currently has 26 active clinical trials seeking participants for Arthritis research studies. These trials are conducted in various cities, including Baltimore, Bethesda, Rockville and Annapolis.
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Klein And Associates M D P A, Hagerstown, Maryland
Conditions: Arthritis, Psoriatic
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Klein And Associates M D P A, Hagerstown, Maryland
Conditions: Arthritis, Psoriatic
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Johns Hopkins University, Baltimore, Maryland +1 locations
Conditions: Arthritis, Psoriatic
Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
Recruiting
Background: Inflammation can play a role in diseases like heart disease and rheumatoid arthritis. PET scans can help detect inflammation. Two new drugs may create better PET images. Objective: To see if the drugs [11C]ER176 and [11C]MC1 can help image inflammation. Eligibility: People ages 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM). Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed. Design: Healthy participants will be sc... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/21/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Recruiting
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Klein and Associates, M.D., P.A., Hagerstown, Maryland
Conditions: Psoriatic Arthritis
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland +2 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA
Recruiting
This multicenter, prospective, interventional trial is designed to assess the outcome of subjects with symptomatic knee osteoarthritis (OA) that are randomized to treatment with either genicular artery embolization (GAE) using Embosphere Microspheres or steroid injection over a period of 24 months.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/15/2024
Locations: Johns Hopkins Medicine, Baltimore, Maryland
Conditions: Knee Osteoarthritis
Natural History and Development of Spondyloarthritis
Recruiting
Background: - Spondyloarthritis (SpA) is a group of bone and joint disorders that may cause back and joint pain and stiffness. In some cases, SpA can lead to abnormal bone growth affecting the joints and spine. Some patients have SpA without ever developing these growths, while others develop them after only a few years. Researchers are interested in studying people with SpA and their relatives to determine which people are more likely to develop more severe conditions. Objectives: - To ident... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
03/14/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Arthritis, Spondylitis, Ankylosing
RA-PRO PRAGMATIC TRIAL
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Johns Hopkins University, Baltimore, Maryland
Conditions: Rheumatoid Arthritis
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain
Recruiting
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Knee Osteoarthritis
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
Recruiting
The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the PMA device, data from this post-approval study must be submitted to FDA in a PMA Post-Approval Study Report per the requirements set forth in the approval.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/07/2024
Locations: Department of Orthopedic Surgery, Johns Hopkins Outpatient Center, Baltimore, Maryland
Conditions: Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
Innovations in Genicular Outcomes Registry
Recruiting
The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs [NSAIDs]).
Gender:
All
Ages:
All
Trial Updated:
03/01/2024
Locations: Sinai Hospital of Baltimore, Baltimore, Maryland
Conditions: Knee Osteoarthritis